206 related articles for article (PubMed ID: 27223813)
1. Oral vinorelbine plus cisplatin versus pemetrexed plus cisplatin as first-line treatment of advanced non-squamous non-small-cell lung cancer: cost minimization analysis in 12 European countries.
Grossi F; Bennouna J; Havel L; Hochmair M; Almodovar T
Curr Med Res Opin; 2016 Sep; 32(9):1577-84. PubMed ID: 27223813
[TBL] [Abstract][Full Text] [Related]
2. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
[TBL] [Abstract][Full Text] [Related]
3. Oral vinorelbine plus cisplatin as first-line chemotherapy in nonsquamous non-small-cell lung cancer: final results of an International randomized phase II study (NAVotrial 01).
Bennouna J; Havel L; Krzakowski M; Kollmeier J; Gervais R; Dansin E; Serke M; Favaretto A; Szczesna A; Cobo M; Ciuffreda L; Jassem J; Nicolini M; Ramlau R; Amoroso D; Melotti B; Almodovar T; Riggi M; Caux NR; Vaissière N; Tan EH
Clin Lung Cancer; 2014 Jul; 15(4):258-65. PubMed ID: 24954228
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of three regimens using vinorelbine (Navelbine) for non-small cell lung cancer.
Hillner BE; Smith TJ
Semin Oncol; 1996 Apr; 23(2 Suppl 5):25-30. PubMed ID: 8610234
[TBL] [Abstract][Full Text] [Related]
5. Vinorelbine in advanced non-small cell lung cancer. A pharmacoeconomic review.
Coukell AJ; Noble S; Faulds D
Pharmacoeconomics; 1999 Apr; 15(4):405-17. PubMed ID: 10537959
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of vinorelbine alone or vinorelbine plus cisplatin for stage IV NSCLC.
Evans WK
Oncology (Williston Park); 1998 Mar; 12(3 Suppl 4):18-25; discussion 25-6. PubMed ID: 9556779
[TBL] [Abstract][Full Text] [Related]
7. Cost-minimization analysis for Portugal of five doublet chemotherapy regimens from two phase III trials in the treatment of advanced non-small cell lung cancer.
Pimentel FL; Bhalla S; Laranjeira L; Guerreiro M
Lung Cancer; 2006 Jun; 52(3):365-71. PubMed ID: 16650499
[TBL] [Abstract][Full Text] [Related]
8. A three-arm trial of vinorelbine (Navelbine) plus cisplatin, vindesine plus cisplatin, and single-agent vinorelbine in the treatment of non-small cell lung cancer: an expanded analysis.
Le Chevalier T; Pujol JL; Douillard JY; Alberola V; Monnier A; Riviere A; Lianes P; Chomy P; Cigolari S; Besson F
Semin Oncol; 1994 Oct; 21(5 Suppl 10):28-33; discussion 33-4. PubMed ID: 7973766
[TBL] [Abstract][Full Text] [Related]
9. Paclitaxel: a pharmacoeconomic review of its use in non-small cell lung cancer.
Plosker GL; Hurst M
Pharmacoeconomics; 2001; 19(11):1111-34. PubMed ID: 11735678
[TBL] [Abstract][Full Text] [Related]
10. Overview of economic analysis of Le Chevalier Vinorelbine Study.
Hillner BE; Smith TJ
Oncology (Williston Park); 1998 Mar; 12(3 Suppl 4):14-6; discussion 17. PubMed ID: 9556778
[TBL] [Abstract][Full Text] [Related]
11. Economic evaluation of a randomized clinical trial comparing vinorelbine, vinorelbine plus cisplatin, and vindesine plus cisplatin for non-small-cell lung cancer.
Smith TJ; Hillner BE; Neighbors DM; McSorley PA; Le Chevalier T
J Clin Oncol; 1995 Sep; 13(9):2166-73. PubMed ID: 7666075
[TBL] [Abstract][Full Text] [Related]
12. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients.
Le Chevalier T; Brisgand D; Douillard JY; Pujol JL; Alberola V; Monnier A; Riviere A; Lianes P; Chomy P; Cigolari S
J Clin Oncol; 1994 Feb; 12(2):360-7. PubMed ID: 8113844
[TBL] [Abstract][Full Text] [Related]
13. Economic analysis of vinorelbine plus cisplatin versus paclitaxel plus carboplatin for advanced non-small-cell lung cancer.
Ramsey SD; Moinpour CM; Lovato LC; Crowley JJ; Grevstad P; Presant CA; Rivkin SE; Kelly K; Gandara DR
J Natl Cancer Inst; 2002 Feb; 94(4):291-7. PubMed ID: 11854391
[TBL] [Abstract][Full Text] [Related]
14. A randomized phase II study of docetaxel or vinorelbine in combination with cisplatin against inoperable, chemo-naïve non-small-cell lung cancer in Taiwan.
Chen YM; Perng RP; Shih JF; Tsai CM; Whang-Peng J
Lung Cancer; 2007 Jun; 56(3):363-9. PubMed ID: 17306906
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of pemetrexed plus cisplatin as first-line therapy for advanced nonsquamous non-small cell lung cancer.
Klein R; Muehlenbein C; Liepa AM; Babineaux S; Wielage R; Schwartzberg L
J Thorac Oncol; 2009 Nov; 4(11):1404-14. PubMed ID: 19786904
[TBL] [Abstract][Full Text] [Related]
16. Vinorelbine. A review of its pharmacological properties and clinical use in cancer chemotherapy.
Goa KL; Faulds D
Drugs Aging; 1994 Sep; 5(3):200-34. PubMed ID: 7803948
[TBL] [Abstract][Full Text] [Related]
17. Three-Year Follow-Up of a Randomized Phase II Trial on Refinement of Early-Stage NSCLC Adjuvant Chemotherapy with Cisplatin and Pemetrexed versus Cisplatin and Vinorelbine (the TREAT Study).
Kreuter M; Vansteenkiste J; Fischer JR; Eberhardt WE; Zabeck H; Kollmeier J; Serke M; Frickhofen N; Reck M; Engel-Riedel W; Neumann S; Thomeer M; Schumann C; De Leyn P; Graeter T; Stamatis G; Griesinger F; Thomas M;
J Thorac Oncol; 2016 Jan; 11(1):85-93. PubMed ID: 26762743
[TBL] [Abstract][Full Text] [Related]
18. [Oral vinorelbine: pharmacology and treatment outcome in non-small cell bronchial carcinoma and breast carcinoma].
Bartsch V
Onkologie; 2006 Mar; 29 Suppl 1():1-28. PubMed ID: 16534241
[TBL] [Abstract][Full Text] [Related]
19. The cost-effectiveness of navelbine alone or in combination with cisplatin in comparison to other chemotherapy regimens and best supportive care in stage IV non-small cell lung cancer.
Evans WK; Le Chevalier T
Eur J Cancer; 1996 Dec; 32A(13):2249-55. PubMed ID: 9038606
[TBL] [Abstract][Full Text] [Related]
20. Time-Series Modeling and Simulation for Comparative Cost-Effective Analysis in Cancer Chemotherapy: An Application to Platinum-Based Regimens for Advanced Non-small Cell Lung Cancer.
Chisaki Y; Nakamura N; Yano Y
Biol Pharm Bull; 2017; 40(1):73-81. PubMed ID: 28049952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]